Literature DB >> 31239155

LncRNA NEAT1-MicroRNA-140 axis exacerbates nonalcoholic fatty liver through interrupting AMPK/SREBP-1 signaling.

Yunfu Sun1, Yu Song2, Changsheng Liu3, Jianli Geng2.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a severe liver disease, which influences the health of people worldwide. However, the mechanism modulating the pathogenesis of NAFLD remains elusive. It was reported that nuclear enriched abundant transcript 1 (NEAT1) and microRNA-140 (miR-140) could regulate lipogenesis, but whether they could influence NAFLD are still unknown.
METHODS: HepG2 cells were treated by free fatty acids (FFA) to establish the model of NAFLD in vitro, and C57 mice were treated by high-fat diet to establish the model of NAFLD in vivo. Cell transfection was applied to regulate the expression of NEAT1 and miR-140. Western blotting and qRT-PCR were applied for measuring expression of protein and mRNA, respectively. HE staining and Oil Red O staining were used for observing liver tissues.
RESULTS: NEAT1 and miR-140 are upregulated in hepacytes under the NAFLD conditions. NEAT1 directly binds to miR-140 and acts synergistically with miR-140 to exacerbate the progression of NAFLD. Reciprocally, silence of miR-140 or NEAT1 alleviates the severity of NAFLD. The mechanistical study shows that the axis of NEAT1-miR-140 inactivates AMPK/SREBP-1 signaling during the NAFLD. .
CONCLUSION: The NEAT1-miR-140 axis play a crucial role in modulation of NAFLD via inactivation of AMPK/SREBP1 signaling. This study may provide a novel insight for the treatment of NAFLD.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AMPK/SREBP-1; MicroRNA-140; NAFLD; NEAT1

Mesh:

Substances:

Year:  2019        PMID: 31239155     DOI: 10.1016/j.bbrc.2019.06.104

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Long Noncoding RNAs and Human Liver Disease.

Authors:  Johanna K DiStefano; Glenn S Gerhard
Journal:  Annu Rev Pathol       Date:  2021-08-20       Impact factor: 32.350

Review 2.  LncRNA-Mediated Adipogenesis in Different Adipocytes.

Authors:  Peiwen Zhang; Shuang Wu; Yuxu He; Xinrong Li; Yan Zhu; Xutao Lin; Lei Chen; Ye Zhao; Lili Niu; Shunhua Zhang; Xuewei Li; Li Zhu; Linyuan Shen
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

3.  The lncRNA Gm15622 stimulates SREBP-1c expression and hepatic lipid accumulation by sponging the miR-742-3p in mice.

Authors:  Minjuan Ma; Rui Duan; Lulu Shen; Mengting Liu; Yaya Ji; Hao Zhou; Changxian Li; Tingming Liang; Xiangcheng Li; Li Guo
Journal:  J Lipid Res       Date:  2020-03-30       Impact factor: 5.922

4.  LncRNA NEAT1/microRNA-129-5p/SOCS2 axis regulates liver fibrosis in alcoholic steatohepatitis.

Authors:  Junfeng Ye; Yuanqiang Lin; Ying Yu; Di Sun
Journal:  J Transl Med       Date:  2020-11-24       Impact factor: 5.531

5.  Upregulated lncRNA HCG18 in Patients with Non-Alcoholic Fatty Liver Disease and Its Regulatory Effect on Insulin Resistance.

Authors:  Yu Xia; Yanxia Zhang; Huiyun Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-12-03       Impact factor: 3.168

6.  Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p/GRIA3.

Authors:  Min-Jie Hu; Mei Long; Rong-Juan Dai
Journal:  Mol Cell Biochem       Date:  2021-10-15       Impact factor: 3.396

7.  Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2.

Authors:  Xiaomeng Chen; Hong Ma; Yan Gao; Ye Jin; Wei Ning; Yue Hou; Jianrong Su
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Exploring the Protective Effects and Mechanism of Huaji Jianpi Decoction against Nonalcoholic Fatty Liver Disease by Network Pharmacology and Experimental Validation.

Authors:  Hongkun Xue; Yu Wang; Hongwei Xiang; Qi Song; Guowei Zhang; Jianguo Wang; Shaoqin Ge
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-26       Impact factor: 2.650

Review 9.  Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets.

Authors:  B Alipoor; S Nikouei; F Rezaeinejad; S-N Malakooti-Dehkordi; Z Sabati; H Ghasemi
Journal:  J Endocrinol Invest       Date:  2021-04-01       Impact factor: 4.256

10.  Long non-coding RNA GAS5 contributes to the progression of nonalcoholic fatty liver disease by targeting the microRNA-29a-3p/NOTCH2 axis.

Authors:  Juanjuan Cui; Yang Wang; Haowei Xue
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.